Serum lipids and hemostasis in kidney allograft recipients treated with fluvastatin (Lescol) for 3 months.
Malyszko
J S
JS
Department of Nephrology and Internal Medicine, Bialystok School of Medicine, Bialystok, Poland.
Malyszko
J
J
Mysliwiec
M
M
D000328:Adult; D016572:Cyclosporine / Q000627:therapeutic use; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use*; D005260:Female; D000077340:Fluvastatin; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000517:prevention & control; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D011183:Postoperative Complications / Q000517:prevention & control; D013997:Time Factors
D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007166:Immunosuppressive Agents; D007211:Indoles; D008055:Lipids; D000077340:Fluvastatin; D016572:Cyclosporine